Patient Access
April 25, 2024
Our Commitment to Patients Means Never Stop Evolving - Our Patient Access Philosophy
Tolga Tanguler, Alnylam's Chief Commercial Officer discusses Alnylam's Patient Access Philosophy and approach to access
Read More ›
May 9, 2022
Building a Collaborative Framework for Facilitating Patient Access to Innovative Therapies
Alnylam worked with leading European economists and other healthcare experts to develop what we call the Value-Based Negotiation Framework (VBNF) to help...
Read More ›
December 21, 2021
Alnylam Publishes 2021 Patient Access Philosophy Report
Alnylam has published its 2021 Patient Access Philosophy Report detailing its actions as a company to provide access to its medicines for those who may...
Read More ›
December 7, 2020
Alnylam Publishes Its 1st-Ever Rare Disease Trend Report
Alnylam's 2020 Rare Disease Trend Report features findings from interviews with 30 U.S. payer and plan decision-makers about barriers to orphan drug access.
Read More ›
December 7, 2020
Alnylam Releases 2nd Annual Patient Access Philosophy Report
The 2020 Alnylam Patient Access Philosophy Report details Alnylam's progress against key metrics related to patient access to its innovative RNAi therapeutics.
Read More ›
October 1, 2020
A New European Biotech Social Pact
The European Pact builds on Alnylam’s own pledge, encouraging biotech companies to be a force for good in partnering with European authorities, citizens and...
Read More ›
September 2, 2020
With Innovation in Market Access, European Patients Can Fully Experience Biotech’s Transfo ...
What’s needed is a larger measure of creativity, flexibility and coordination around market access. This must become the new baseline environment in which...
Read More ›
December 12, 2019
Building Bridges to Support Patients’ Care
Supporting patients and their caregivers by facilitating access to innovative treatments is at the core of our Patient Access Philosophy.
Read More ›
September 9, 2019
Alnylam's Patient Access Philosophy - Our Progress
Nearly two years ago – before we launched our first product – we made a commitment to strive toward broad patient access to our medicines. In our view...
Read More ›
